Original Research J Clin Psychiatry January 2024

Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study

JCP 2024;85(1):10.4088/JCP.23m14966

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2024;85(1):10.4088/JCP.23m14966 Clinical Summary Acute bipolar mania often requires rapid symptom control, yet many patients do not find a treatment option they can both tolerate and stay on. This study addresses whether iloperidone can reduce manic symptoms in adults with bipolar I disorder while maintaining the relatively favorable akathisia and extrapyramidal side effect profile that can influence antipsychotic selection. FAQ Does iloperidone work for acute bipolar I mania? 13 questions
Key Takeaways In this 28-day inpatient trial, iloperidone was started with a 4-day titration to 24 mg/d (12 mg twice daily), or 12 mg/d in CYP2D6 poor metabolizers, which is relevant when planning acute treatment and managing QTc risk. 6 takeaways Clinical Guide How should clinicians initiate iloperidone for an adult with acute bipolar I mania based on this trial? 7 steps Clinical Guide How should clinicians monitor safety during the first month of iloperidone treatment for acute bipolar mania? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe